Abstract:Among the cancer patient population, resistance to therapy is a major cause for therapeutic failure and for human sufferings, especially for the cancer with poor prognosis. Therefore, finding factors that contribute to drug resistance is a major research interest. In this study, we have investigated whether polymorphisms in genes that control import/export of drugs (MDR1) and that repair DNA adducts (ERCC1) are involved with drug resistance in non-small cell lung cancer (NSCLC) patients. We have recruited 95 patients with advanced NSCLC (stages IIIB-IV) who were specifically treated with platinum-based chemotherapy. We used the ligase detection reactions assay (LDR) to detect polymorphisms in ERCC1 118C/T, and MDR1 2677T/A, E1/-129T/C, and C3435T in peripheral blood lymphocytes from the patients. The haplotype of MDR1 gene single nucleotide polymorphisms (SNPs) were analyzed using the SHEsis software platform on line. We found that none of the single polymorphisms was associated with treatment response or related toxicity. However, patients carrying at least one variant MDR1 2677 T allele was associated with a significantly increased risk of drug resistance (OR=1.844, 95% CI=1.01-3.53, P=0.04) but also with a significantly increased risk of gastrointestinal toxicity (P=0.03) but not hemato-, hepato- or nephro-toxicities. Moreover, we analyzed the haplotypes of the three polymorphisms in MDR1. The patients harboring the E1/-129T-2677T-3435C haplotype had a significantly better response to chemotherapy compared with those having the other haplotypes (P=0.02, 95% CI=1.20-25.87), and a marginally significant association with increased risk of gastrointestinal toxicity (P=0.02, 95% CI=1.15-3.88). Our results suggested that gene polymorphisms in MDR1G2677T/A may be a predictive marker of platinum-based treatment response and of secondary effects, especially gastrointestinal toxicity for advanced NSCLC patients.

XRCC1 Arg399Gln and Arg194Trp Polymorphisms Regulate XRCC1 Expression and Chemoresistance of Non-Small Cell Lung Cancer Cells

XRCC1 Polymorphisms and Severe Toxicity in Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy in Chinese Population

Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.

Single Nucleotide Polymorphisms in XRCC1 and Clinical Response to Platin-based Chemotherapy in Advanced Non-small Cell Lung Cancer

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

XRCC1 Genetic Polymorphisms and Sensitivity to Platinum-Based Drugs in Non-Small Cell Lung Cancer: an Update Meta-Analysis Based on 4708 Subjects.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis

[XRCC1 and XPD Genetic Polymorphisms Predict Clinical Responses to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer].

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

XRCC1 Polymorphisms Are Associated with Cervical Cancer Risk and Response to Chemotherapy: a Systematic Review and Meta-Analysis.

DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Effect of X-ray Repair Cross Complementing Group 1 Polymorphisms on the Efficacy of Platinum-Based Chemotherapy in Patients with Nonsmall Cell Lung Cancer.

Single nucleotide polymorphisms in XRCC1,XPD and platinum prognosis in non-small-cell lung cancer patients

XRCC1 Polymorphism and Overall Survival in Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy

Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy

Relationship between gene polymorphism of XRCC1 and sensitivity of platinum-based chemotherapy in patients with advanced non-small cell lung cancer:a Meta-analysis

Association of MDR1 and ERCC1 Polymorphisms with Response and Toxicity to Cisplatin-Based Chemotherapy in Non-Small-cell Lung Cancer Patients.

No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.